The 3D printed drugs marketwas valued at US$ 28.52million in 2019 and is expected to grow at a CAGR of 9.1% from 2020to 2027 to reach US$57.03million by 2027.
Tablet Segment to Accelerate at a Fast Pace over the Forecast Period
3D printed drugs are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, because of which these high-dose medicines need not to be swallowed intact. The main idea behind 3D printing drugs is to design and develop medicines that are suited to an individual's needs.The global 3D printed drugs market is driven by factors such asincreasing adoption of personalized drugs. Additionally, growing research and development activities,coupled with increasing prevalence of dysphagia,is also anticipated to drive the 3D market growth during the forecast period. However, the usage of 3D printing to develop illegal drugs restrains the growth of the market. The developing healthcare infrastructure and increasing awareness regarding 3D printing in pharmaceuticals generate lucrative opportunities for the growth of the market.
Get Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00010199/
The global 3D printed drugs market, based on the dosage forms, is segmented into tablets, capsules, multi drug implant, nanoparticles, solutions, and other dosage forms. The tablet segment held the largest share of the market in 2019, and it is further estimated to register the highest CAGR during the forecast period. The growth of the 3D printed drugs market is ascribed to the growing emphasis on personalized medicines and extensive R&D activities.
Leading companies operating in the 3D printed drugs market are Aprecia Pharmaceuticals, LLC, FabRx Ltd, Cycle Pharmaceuticals, GlaxoSmithKline PLC., Astrazeneca, Tvasta, and Merck KGGA, among others.
Increasing Adoption of Personalized Drugs
Personalized medicine is a growing area of treatment that relies on specific drug delivery and dosing. As per a study published by PMC, personalized medicines accounted for only 5% of the new FDA approved molecular entities in 2005; whereas, in 2016, they accounted for more than 25%. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, and expect to increase their investment by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the number of personalized medicines in development over the coming five years.
3D printing offers the possibility of creating a personalized medicine system through automated control over drug dose and is suitable for both low and high drug concentrations. These advantages allow drug companies to not only boost efficacy and adherence, but also contribute to their brand longevity by expanding and capturing market share with other dosage forms. Through this breakthrough method of manufacturing and its fast-melt capabilities, there is an ability to overcome several obstacles, thereby contributing to better patient outcomes in the solid dose market. For instance, FabRx Ltd. completed the world's first in-human clinical study using their proprietary Printlets technology, which relies on personalized 3D printed dosage forms to treat children with a rare metabolic disease. Additionally, the same company launched the first pharmaceutical 3D printer, M3DIMAKER, for the manufacture of personalized medicines in April 2020. Hence, there is a need for new manufacturing systems to prepare personalized medicines, and this potential application of 3D printing for rare diseases is countless. It could help make the medication safer and more attractive to children, thereby propelling the growth of the 3D printed drugs market.
Based on technology, the 3D printed drugs market is segmented into inkjet printing, direct write, zip dose, thermal inkjet printing, fused deposition modeling, powder bed printing, stereolithography (SLA), and semi solid extrusion (SSE). The zip dose technology segmentheld the largest share of the market; moreover, it is expected to register the highest CAGR during the forecast period.
Product launches and FDA approvalsis a commonly adopted strategy by companies to expand their footprint worldwide and meet the growing demand as the strategy allows them to expand their product portfolios.
The 3D printed drugs marketplayers also adopt the strategy ofcollaborations, which enables them enlarge their global customer base,alongside helping them maintain their brand names.
Purchase this Premium Report at https://www.theinsightpartners.com/buy/TIPRE00010199/
Contact Person: Sameer Joshi